LL-37 (Cathelicidin)

LL-37 is an endogenous human antimicrobial peptide (cathelicidin) that plays a role in innate immunity. Research explores its antimicrobial, wound healing, and immunomodulatory properties.

At a Glance

Summary: Provides direct antimicrobial activity through membrane disruption while modulating immune responses and promoting wound healing. Mechanisms (reported/proposed across domains): Antimicrobial / infection • Disrupts bacterial membranes through electrostatic interactions with phospholipids, and is active against gram-positive, gram-negative bacteria, fungi, and enveloped viruses. • May...

Safety Profile

Investigational - Higher Risk Profile

Research Dosing

Dose: 50–200 mcg · Route: Subcutaneous (SC) · Topical · Frequency: 1× daily · Duration: 2–4 weeks

Categories

  • Research Only
  • Antimicrobial
  • Immune Modulation
  • Wound Healing
  • Biofilm Disruption
  • Innate Immunity
  • Higher Risk
  • Preclinical Evidence
  • Not FDA Approved

Related Peptides

The Leading Community for Trusted Peptide Research & Insights

Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.